© 2006 VistaGen Therapeutics, Inc.
Home Contact
   Home
   Contact
This page lists relevant publications, which relate to VistaGen's technologies and drug programs in the fields of stem cell biology, CNS drug development and metabolic diseases.

Click on the title to view or download the PDF document.

   Stem Cell Related

   Drug Development Related
  1. Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice
    Parish et al. J. Clin. Invest., 2008;149-160

  2. Stem-Cell-Based Strategies for the Treatment of Parkinson's Disease
    Parish & Arenas Neurogenerative Diseases 2007;339-347

  3. In situ-produced 7-chloro-kynurenic acid increases phasic activity of midbrain dopamine neurons
    Linderholm et al. Society for Neuroscience, Atlanta, GA, October 2006

  4. Kynurenate and 7-chlorokynurenate formation in chronically epileptic rats
    Wu et al. Epilepsia 2005;46:1-7

  5. Kynurenate production by cultured human astrocytes
    Kiss et al. J. Neural Transm. 2003;110:1-14

  6. Rewiring the Parkinsonian brain
    Fricker-Gates & Dunnett Nat. Medicine 2002;8:105-106

  7. L-4-chlorokynurenine attenuates kainate-induced seizures and lesions in the rat
    Wu et al. Exp. Neurol. 2002;177:222-232

  8. Manipulation of brain kynurenines: Glial targets, neuronal effects, and clinical opportunities
    Schwarcz & Pellicciari J. Pharm. Exp. Thera. 2002;303:1-10

  9. Excitotoxic injury stimulates pro-drug-induced 7-chlorokynurenate formation in the rat striaturm in vivo
    Lee & Schwarcz Neurosci. Lett. 2001;304:185-188

  10. In situ produced 7-chlorokynurenate provides protection against quinolinate- and malonate-induced neurotoxicity in the rat striatum
    Guidetti et al. Exp. Neurol. 2000;163:123-130

  11. Systemic administration of 4-chlorokynurenine in rats: Rapid formation of the glycine-b receptor antagonist 7-chlorokynurenic acid in the spinal cord
    Schwarcz & Guidetti Society for Neuroscience, San Diego, CA, October 2004

 
 
Publications